Chugai Pharmaceutical Co Ltd ADR (CHGCY) fair value: what the stock is really worth
We calculate from audited financials what Chugai Pharmaceutical Co Ltd ADR is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
- Compare price with fair valuebelow fair value = cheap, above = expensive
- Check the quality50 and up solid, 75 and up strong
- Watch it or check another stockalert when fair value or trend changes
At a glance
Chugai Pharmaceutical Co Ltd ADR
CHGCY · US
A strong business, but trading 17% above our fair value of $18.41.
As of Sep 8, 2026, the fair value of Chugai Pharmaceutical Co Ltd ADR is $18.41 per share against a price of $21.59, so the fair value sits 15% below the price. A model estimate from reported figures, not an analyst target.
Fair value as of: Sep 8, 2026
From 24 valuation models · updated today
Fair value updated Sep 8, 2026, revised from $18.12 to $18.41 (+1.6%) since Sep 6, 2026. Share price +3.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A fairly wide model range ($11.03 to $24.71) leaves room in how you read the outcome.
- The price sits in the upper half of our model range, so the margin of safety is thin.
- Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 8, 2026.
How to read this chart
60‑month range $10.34 – $33.48 · fair‑value band $11.03 – $24.71 · the $21.59 price screens above the $18.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 8, 2026.
Analysis
Chugai Pharmaceutical Co Ltd ADR (CHGCY) currently trades at $21.59, while our model-based Fair Value estimate is $18.41, implying the stock looks roughly 17.3% overvalued today. The Quality Score stands at 78/100 (high quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $18.02 per share, and 3 of the 24 models we run sit above the $21.59 price. Bear case: the Asset-Based group reads lowest at $2.85, and 21 of the 24 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Chugai Pharmaceutical Co Ltd ADR generated revenue of ¥1.3T at a net margin of 35.0%. Revenue grew 11.5% year over year. It earns a return on equity of 23.7%. The balance sheet holds a net cash position of ¥401B. Fundamentals as of Sep 8, 2026
Scenario range: $11.03 (bear) to $24.71 (bull), the price of $21.59 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 36% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −18% fair-value upside, at −15%, CHGCY screens cheaper than that median.
Fair Value models
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
All 24 models by family
Widest divergence: DCF Models ($18.02) versus Asset-Based ($2.85). Highest evidence: FCF DCF (79).
Notify me when CHGCY reaches fair value
Put CHGCY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 8, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Full company description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Chugai Pharmaceutical Co Ltd ADR reported revenue of ¥1.3T in FY2025 versus ¥1,000B in FY2021, a compound +7.2%/yr. Reported net income was ¥455B in FY2025, compounding +10.7%/yr from FY2021.
of which total revenue +10.6 % · buybacks/dilution +0.0 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
CHGCY screens 17% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 74 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
What the price implies (reverse DCF)
The inverse question: what free-cash-flow growth must Chugai Pharmaceutical Co Ltd ADR deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.
The price demands roughly the growth the company recently delivered. Ranking of the largest stocks →
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Sep 8, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,149 | $389.47 | −66% |
| Johnson & Johnson, JNJ | $275.23 | $169.04 | −39% |
| AbbVie Inc ABBV | $256.46 | $67.72 | −74% |
| Roche Holding RO | CHF 374.60 | CHF 306.54 | −18% |
| Merck & Co MRK | €131.98 | €101.38 | −23% |
| Novartis AG NOVN | CHF 125.46 | CHF 115.09 | −8% |
| Novo Nordisk A/S NOVOB | kr 298.95 | kr 409.46 | +37% |
| Amgen Inc AMGN | $437.23 | $252.02 | −42% |
| Gilead Sciences, Inc GILD | $151.00 | $146.50 | −3% |
| Pfizer Inc PFE | $28.45 | $24.87 | −13% |
Compare Chugai Pharmaceutical Co Ltd ADR with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Chugai Pharmaceutical Co Ltd ADR (CHGCY) overvalued or undervalued?
What is the fair value of CHGCY?
What is the quality score of CHGCY?
What is the price target for Chugai Pharmaceutical Co Ltd ADR (CHGCY)?
What is the Chugai Pharmaceutical Co Ltd ADR stock forecast for 2026?
What is the revenue of Chugai Pharmaceutical Co Ltd ADR (CHGCY)?
What is the net profit margin of CHGCY?
Does Chugai Pharmaceutical Co Ltd ADR pay a dividend?
What growth is priced into Chugai Pharmaceutical Co Ltd ADR (CHGCY)?
What discount rate (WACC) does the fair value of CHGCY use?
Watch Chugai Pharmaceutical Co Ltd ADR in the live analysis
One click puts Chugai Pharmaceutical Co Ltd ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.